Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CorMedix stock | 5.79

Own CorMedix stock in just a few minutes.

Posted

Fact checked

CorMedix Inc is a biotechnology business based in the US. CorMedix shares (CRMD) are listed on the NYSE and all prices are listed in US Dollars. CorMedix employs 30 staff and has a trailing 12-month revenue of around USD$174,806.

How to buy shares in CorMedix

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CorMedix. Find the stock by name or ticker symbol: CRMD. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CorMedix reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$5.79, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of CorMedix, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CorMedix. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted CorMedix's share price?

Since the stock market crash in March caused by coronavirus, CorMedix's share price has had significant negative movement.

Its last market close was USD$5.79, which is 9.39% down on its pre-crash value of USD$6.39 and 168.06% up on the lowest point reached during the March crash when the shares fell as low as USD$2.16.

If you had bought USD$1,000 worth of CorMedix shares at the start of February 2020, those shares would have been worth USD$405.56 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$847.71.

CorMedix share price

Use our graph to track the performance of CRMD stocks over time.

CorMedix shares at a glance

Information last updated 2020-10-20.
Latest market close USD$5.79
52-week range USD$2.16 - USD$7.97
50-day moving average USD$5.2489
200-day moving average USD$4.9558
Wall St. target price USD$15.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.644

Buy CorMedix shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CorMedix stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CorMedix price performance over time

Historical closes compared with the close of $5.79 from 2020-11-16

1 week (2020-11-17) -3.82%
1 month (2020-10-23) -1.03%
3 months (2020-08-25) 19.88%
6 months (2020-05-23) N/A
1 year (2019-11-25) -5.08%
2 years (2018-11-23) 332.09%
3 years (2017-11-24) 1,013.46%
5 years (2015-11-25) 151.74%

CorMedix financials

Revenue TTM USD$174,806
Gross profit TTM USD$-89,968
Return on assets TTM -60.53%
Return on equity TTM -113.78%
Profit margin 0%
Book value $0.709
Market capitalisation USD$180.6 million

TTM: trailing 12 months

Shorting CorMedix shares

There are currently 3.6 million CorMedix shares held short by investors – that's known as CorMedix's "short interest". This figure is 4.7% down from 3.7 million last month.

There are a few different ways that this level of interest in shorting CorMedix shares can be evaluated.

CorMedix's "short interest ratio" (SIR)

CorMedix's "short interest ratio" (SIR) is the quantity of CorMedix shares currently shorted divided by the average quantity of CorMedix shares traded daily (recently around 711863.14741036). CorMedix's SIR currently stands at 5.02. In other words for every 100,000 CorMedix shares traded daily on the market, roughly 5020 shares are currently held short.

However CorMedix's short interest can also be evaluated against the total number of CorMedix shares, or, against the total number of tradable CorMedix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CorMedix's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 CorMedix shares in existence, roughly 110 shares are currently held short) or 0.1165% of the tradable shares (for every 100,000 tradable CorMedix shares, roughly 117 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CorMedix.

Find out more about how you can short CorMedix stock.

CorMedix share dividends

We're not expecting CorMedix to pay a dividend over the next 12 months.

Have CorMedix's shares ever split?

CorMedix's shares were split on a 1:5 basis on 26 March 2019. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CorMedix shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for CorMedix shares which in turn could have impacted CorMedix's share price.

CorMedix share price volatility

Over the last 12 months, CorMedix's shares have ranged in value from as little as $2.16 up to $7.97. A popular way to gauge a stock's volatility is its "beta".

CRMD.US volatility(beta: 2.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while CorMedix's is 2.3988. This would suggest that CorMedix's shares are significantly more volatile than the average for this exchange and represent a higher risk.

CorMedix overview

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site